ArticleCureus2026
Clinico-Hematological and Immunophenotypic Profile of Leukemia Patients at a Tertiary Care Center in Jharkhand, India: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Leukemia represents a significant and rising health burden in India. Despite this, a government-maintained population-based cancer registry is lacking in Jharkhand. This study aimed to characterizethe clinico-hematological and immunophenotypic profile of newly diagnosed leukemia cases from a tertiary care center in this underrepresented region. Methods This was a hospital-based, cross-sectional study conducted in the Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, India, over a two-year period (February 2024 to January 2026). A total of 151 newly diagnosed leukemia cases were evaluated. Peripheral blood smear, bone marrow aspiration, and immunophenotyping by flow cytometry were performed in accordance with the World Health Organization Classification of haematolymphoid tumours, Fifth Edition (WHO-HAEM5) and International Consensus Classification (ICC) criteria. Data were recorded in Microsoft Excel (Redmond, USA) and analyzed using Jamovi v2.7.17. Results Of the 151 patients, the mean age was 36.7 ± 19.8 years, with a male predominance (74.2%; M:F = 2.9:1). The majority of patients were from a rural background (79.5%). Chronic myeloid leukemia, chronic phase (CML-CP) was the most frequent diagnosis (27.8%), followed by acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) (24.5% each), chronic lymphocytic leukemia (CLL) (12.6%), T-cell acute lymphoblastic leukemia (T-ALL) (8.6%), and mixed phenotype acute leukemia (MPAL) (2.0%). Fever and bleeding manifestations were more prevalent in acute leukemias (p < 0.001). Severe thrombocytopenia was almost universal in acute leukemias. CD34-positive AML showed higher WBC counts, higher blast percentages, and lower hemoglobin and platelet counts compared to CD34-negative cases (all p < 0.05). CD10-negative B-ALL showed higher WBC counts (p < 0.001), higher blast percentages (p = 0.008), and lower platelet counts (p = 0.048) compared to CD10-positive cases; these findings should be regarded as exploratory given the small subgroup size (n = 5). Conclusions This study establishes a baseline clinico-hematological and immunophenotypic profile of leukemias in Jharkhand. These findings reflect the need for a state-level population-based cancer registry and strengthened diagnostic infrastructure in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.